-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
Time Posted:2024-05-20 16:52
A novel inhaled anti-IL-4Rα monoclonal antibody has been introduced. This drug is also used to treat respiratory diseases such as asthma and COPD. Phase I clinical trials of the anti-IL-4Rα monoclonal antibody have been completed, and Phase II clinical trials have begun.
Time Posted:2024-05-20 16:51
Introducing a highly selective second-generation Nav1.8 inhibitor, an innovative drug for pain treatment, expected to be highly effective and non-addictive. Health Yuan is responsible for subsequent clinical research and application for production of this drug.
Time Posted:2024-05-20 16:51
Acquired rights to an anti-TSLP monoclonal antibody, a drug used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The anti-TSLP monoclonal antibody is currently undergoing Phase II clinical trials for asthma in China.
Time Posted:2024-05-20 16:50
An exclusive license agreement for a new antiviral drug against influenza in Greater China has been reached. The new drug was submitted for production in August and is expected to be launched next year.
Time Posted:2024-05-08 17:16
Recently, the Red Cross Society of China issued a notice on awarding medals and plaques to donors who have made outstanding contributions to the Chinese Red Cross cause in 2023. LiZhu Pharmaceutical Group Co., Ltd. and its parent company, Joincare Pharmaceutical Group Industry Co., Ltd., were awarded the "Special Contribution Award" and the "China Red Cross Charity Medal", respectively.
Time Posted:2024-04-26 16:43
On the evening of April 25, 2024, Health Yuan (600380.SH), a leading manufacturer of respiratory drugs, disclosed its first-quarter performance. From January to March 2024, the company achieved operating revenue of 4.34 billion yuan and net profit attributable to shareholders of 440 million yuan. Sales of the company's key specialized respiratory products made a significant contribution to overall revenue, reaching 417 million yuan in the first quarter, accounting for 9.61% of total revenue.
Q1 Business Development Transaction Overview
Time Posted:2024-04-24 14:29
The first quarter of 2024 has passed quickly. This review summarizes the major business development (BD) transactions in the pharmaceutical field from January to March, providing insights into the current market situation and trends. Based on publicly available information from sources such as Meibai Capital and various listed company announcements, a total of 50 transactions were completed in the Chinese pharmaceutical sector this quarter. This includes 12 license-in transactions, 27 license-out transactions, and 11 domestic transactions. Compared to the 32 transactions in the first quarter of 2022, this represents a 56% increase. It has also been observed that 32 of these 50 transactions originated from information released at the J.P. Morgan Healthcare Conference in the United States at the beginning of 2024.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home